Remember
 
 
Most Discussed Stocks  Most Discussed Stocks through Posts and Reactions on SpeculatingStocks  UGAZ  •  APRN  •  SVMK  •  TLRY  •  GE  •  TRV  •  GLBS  •  SNAP  •  CRON  •  PXS

Biotech Stocks & ETFs, Headlines, and Posts Bucket Watchlist of Biotech Stocks, ETFs, Headlines and Posts

Types of Stocks and ETFs: biotech, biotechnology, biopharma, pharma, etc.















Watchlist of Stocks and ETFs Based on Theme: Companies Related to Biotech.

Generated with SpeculatingStocks Stock Theme Analytics Algorithm™ - More Bucket Watchlists of Stocks.

Important Note: Most of the stocks and ETFs in this list directly relate to biotech; however, a few may just somewhat depend and/or be indirectly related to biotech. As always complete your own due diligence.


Biotech Stocks & ETFs


Symbol
Company / ETF Name
Market Cap





















































6.135B


































127.765B












































































































































































































































































































































































































143.205B
















































161.123M
















66.352B
















































































































258.285B











Recent Biotech Headlines





Recent Biotech Posts (Pulses)




11/14/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



11/14/2018: $ABUS (Arbutus Biopharma Corporation) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



11/12/2018: $BNTC (Benitec Biopharma LTD) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



11/12/2018: $NEXS (Nexus Biopharma, Inc.) is up more than 50%, reaching a new upside threshold. -- Go to this Pulse Post



11/12/2018: $SPHRY (Starpharma Holdings Limited) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



11/12/2018: $APTX Aptinyx announced that exploratory clinical studies of its NYX-2925 provide the first evidence that oral dosing of the product candidate induces pharmacodynamic activities in humans that are understood to be NMDAr-mediated. -- Go to this Pulse Post



11/12/2018: $EPRSQ (EPIRUS Biopharmaceuticals Inc.) is down more than 20%, reaching a new downside threshold. -- Go to this Pulse Post



11/11/2018: $BNTC (Benitec Biopharma LTD) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



11/10/2018: $SPHRY (Starpharma Holdings Limited) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



11/09/2018: $TBPH Theravance Biopharma and Mylan (MYL) confirm FDA approval of Yupelri for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD. -- Go to this Pulse Post



11/09/2018: $TBPH Theravance Biopharma: FDA confirmed approval of Yupelri for COPD. -- Go to this Pulse Post



11/09/2018: $NEXS (Nexus Biopharma, Inc.) is up more than 50%, reaching a new upside threshold. -- Go to this Pulse Post



11/09/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



11/08/2018: $RDHL (RedHill Biopharma Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



11/08/2018: $CUE Cue Biopharma entered Into a multi-target strategic collaboration with LG Chem Life Sciences to develop multiple Immuno-STAT biologics focused in the field of oncology. -- Go to this Pulse Post



11/07/2018: $MESO breaking out today, up 6%+. Could see a new 52-wk high above $8.78 soon. Has strong product partnerships in pharma space. -- Go to this Pulse Post



11/06/2018: $TBPH Theravance Biopharma announced sale of VIBATIV to Cumberland Pharmaceuticals (CPIX) for $25M and tiered royalties of up to 20% on future US net product sales. -- Go to this Pulse Post



11/05/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



11/05/2018: $ABIO (ARCA biopharma, Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



11/04/2018: $INBP (Integrated Biopharma Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



11/04/2018: $SBMFF (Sino Biopharmaceutical Ltd.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



11/04/2018: $ABIO (ARCA biopharma, Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



11/03/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



11/03/2018: $ABIO (ARCA biopharma, Inc.) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



11/02/2018: $ABUS (Arbutus Biopharma Corporation) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



11/02/2018: $ABUS (Arbutus Biopharma Corporation) is up more than 10%, reaching a new upside threshold. -- Go to this Pulse Post



10/30/2018: $NAVB (Navidea Biopharmaceuticals, Inc) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/29/2018: $INNT Innovate Biopharmaceuticals announced positive effect of larazotide acetate on reducing intestinal permeability in NASH preclinical study. -- Go to this Pulse Post



10/27/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



10/26/2018: $MRK confirmed to be entering medical cannabis market with a spinoff. MilliporeSigma to use $UNVC pharmaceutical grade CBD oil. Major JV -- Go to this Pulse Post



10/24/2018: $PRNB Principia Biopharma appointed Dolca Thomas, M.D. as Chief Medical Officer. -- Go to this Pulse Post



10/23/2018: $ALDR Alder BioPharmaceuticals announced 'positive' results from a comparative pharmacokinetic study intended to support the comparability evaluation of the clinical supply for eptinezumab and its planned commercial supply. -- Go to this Pulse Post



10/23/2018: $PFE Pfizer and Bain Capital announce creation of new biopharmaceutical company Cerevel Therapeutics. -- Go to this Pulse Post



10/23/2018: $ENTA Enanta Pharmaceuticals announced 'Positive' Phase 1 Results and dosing has begun in a Phase 2a study to evaluate the safety, pharmacokinetics and antiviral activity of multiple doses of orally administered EDP-938 against respiratory syncytial virus infection in a human challenge study. -- Go to this Pulse Post



10/22/2018: $RDHL RedHill Biopharma announced additional 'positive' data from the MAP US Phase III study of RHB-104 in the treatment of Crohn's Disease at UEGW. -- Go to this Pulse Post



10/22/2018: $TBPH Theravance Biopharma reported results from the exploratory Phase 1b study of the gut-selective pan-Janus kinase (JAK) inhibitor TD-1473. -- Go to this Pulse Post



10/22/2018: $ATNX Athenex presented 'encouraging' efficacy and safety data of Oraxol in the treatment of metastatic breast cancer patients who failed previous chemotherapies in a pharmacokinetics and phase II clinical trial conducted in Taiwan. -- Go to this Pulse Post



10/22/2018: $FLXN Flexion Therapeutics presented results from a Phase 2 clinical trial evaluating the pharmacokinetics and safety of concurrent administration of ZILRETTA in patients with bilateral osteoarthritis. -- Go to this Pulse Post



10/19/2018: $BNTCW (Benitec Biopharma Limited) is up more than 20%, reaching a new upside threshold. -- Go to this Pulse Post



10/19/2018: $PRNB Principia Biopharma granted orphan-drug designation by the FDA for PRN1008 for the treatment of patients with immune thrombocytopenic purpura. -- Go to this Pulse Post



10/18/2018: $EXAS Exact Sciences acquired Biomatrica, a developer, manufacturer and provider of sample preservation technology, including blood and saliva sample collection tubes, to the biotech industry; terms not disclosed. -- Go to this Pulse Post



10/18/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is down more than 10%, reaching a new downside threshold. -- Go to this Pulse Post



10/17/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/17/2018: $BNTCW (Benitec Biopharma Limited) is down more than 50%, reaching a new downside threshold. -- Go to this Pulse Post



10/17/2018: $NEXS (Nexus Biopharma, Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/16/2018: $KERX (Keryx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.27. -- Go to this Pulse Post



10/16/2018: $KERX (Keryx Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 13.59%. -- Go to this Pulse Post



10/16/2018: $KERX (Keryx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 66.28%. -- Go to this Pulse Post



10/16/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.61. -- Go to this Pulse Post



10/16/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 5.68. -- Go to this Pulse Post



10/15/2018: $NEXS (Nexus Biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 2.34. -- Go to this Pulse Post



10/15/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 2.22. -- Go to this Pulse Post



10/15/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 28.90%. -- Go to this Pulse Post



10/15/2018: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 28.17%. -- Go to this Pulse Post



10/15/2018: $BNTCW (Benitec Biopharma Limited) is down more than 50%, reaching a new downside threshold. -- Go to this Pulse Post



10/14/2018: $ABIO (ARCA biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/14/2018: $RDHL (RedHill Biopharma Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/14/2018: $SBBP (Strongbridge Biopharma plc) has significant institutional ownership of at least 20% with institutional ownership of 87.50%. -- Go to this Pulse Post



10/13/2018: $RGRX (Regenerx Biopharmaceuticals Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/12/2018: $HEB (Hemispherx Biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/12/2018: $ABIO (ARCA biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/12/2018: $LABU is a no-brainer here, watch to see if M&A picks up in biotech space, if so biotech could become the market's new darling for now. -- Go to this Pulse Post



10/12/2018: $SPRO Spero Therapeutics has recent positives going on, biotech is showing signs of life as well. -- Go to this Pulse Post



10/12/2018: $BNTCW (Benitec Biopharma Limited) is down more than 50%, reaching a new downside threshold. -- Go to this Pulse Post



10/11/2018: $HEB (Hemispherx Biopharma, Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/11/2018: $TBPH Theravance Biopharma & Mylan (MYL) present data from multiple studies of YUPELRI inhalation solution. -- Go to this Pulse Post



10/10/2018: $SBFM (Sunshine Biopharma, Inc.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/09/2018: $INBP (Integrated Biopharma Inc.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.08. -- Go to this Pulse Post



10/09/2018: $INBP (Integrated Biopharma Inc.) is cash flow positive as of at least the last quarter with Quarterly Cash Flow of $166,000. -- Go to this Pulse Post



10/09/2018: $INBP (Integrated Biopharma Inc.) is profitable as of at least the last quarter with Quarterly Net Income of $818,000. -- Go to this Pulse Post



10/09/2018: $INBP (Integrated Biopharma Inc.) is trading at a trailing PE of less than 25 with a Price to Earnings ratio of only 8.16. -- Go to this Pulse Post



10/08/2018: $ABIO (ARCA biopharma, Inc.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 1. -- Go to this Pulse Post



10/08/2018: $ABIO (ARCA biopharma, Inc.) is significantly more volatile than the overall market with a Beta of 3.80. -- Go to this Pulse Post



10/08/2018: $ABIO (ARCA biopharma, Inc.) has significant institutional ownership of at least 20% with institutional ownership of 28.19%. -- Go to this Pulse Post



10/08/2018: $ALDR (Alder Biopharmaceuticals Inc.) is cash flow negative as of at least the last quarter with Quarterly Net Cash Flow of $(86.2M). -- Go to this Pulse Post



10/08/2018: $ALDR (Alder Biopharmaceuticals Inc.) did not produce a profit last quarter with Quarterly Net Income of $(68.39M). -- Go to this Pulse Post



10/08/2018: $ALDR (Alder Biopharmaceuticals Inc.) is significantly more volatile than the overall market with a Beta of 3.20. -- Go to this Pulse Post



10/08/2018: $ALDR (Alder Biopharmaceuticals Inc.) could become a potential short squeeze opportunity with significant short interest of 19.91%. -- Go to this Pulse Post



10/08/2018: $TBPH Theravance Biopharma presented 'positive' new data from multiple studies of VIBATIV. -- Go to this Pulse Post



10/07/2018: $INBP (Integrated Biopharma Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/06/2018: $BNTCW (Benitec Biopharma Limited) is down more than 50%, reaching a new downside threshold. -- Go to this Pulse Post



10/06/2018: $INBP (Integrated Biopharma Inc.) is down more than 5%, reaching a new downside threshold. -- Go to this Pulse Post



10/05/2018: $CMRX Chimerix announced data from the company's Phase 1 study evaluating the safety and pharmacokinetics of multiple ascending doses of IV brincidofovir in healthy subjects. -- Go to this Pulse Post



10/04/2018: $XTLB (XTL Biopharmaceuticals Ltd.) is up more than 5%, reaching a new upside threshold. -- Go to this Pulse Post



10/04/2018: $TBPH Theravance Biopharma CFO Renee D. Gala notifies of intention to resign effective January 2. -- Go to this Pulse Post



10/03/2018: $SNNA (Sienna Biopharmaceuticals Inc.) has significant institutional ownership of at least 20% with institutional ownership of 47.16%. -- Go to this Pulse Post



10/03/2018: $CRBP Corbus Pharma: USPTO issued U.S. Patent No. 10,085,964 to the Company; patent includes claims covering the use of pharmaceutical compositions comprising lenabasum for the treatment of all fibrotic diseases. -- Go to this Pulse Post



10/02/2018: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/B of at or below a book value of 1 with a Price to Book ratio of only 0.47. -- Go to this Pulse Post



10/02/2018: $SBMFF (Sino Biopharmaceutical Ltd.) is trading at a P/S of at or below sales with a Price to Sales ratio of only 0.66. -- Go to this Pulse Post



10/02/2018: $BNTCW (Benitec Biopharma Limited) is down more than 50%, reaching a new downside threshold. -- Go to this Pulse Post



10/01/2018: $RDY Dr. Reddy's announced termination of license granted to Armis Biopharma for its investigational antibacterial product, DFA-02, for the prophylaxis of surgical site infections. -- Go to this Pulse Post